Business

NervGen Pharma to Participate at Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate

articleNervgen Pharma Corp.February 18, 20265/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-participate-at-upcoming-investor-conferences
NervGen Pharma to Participate at Upcoming Investor Conferences

About this update from Nervgen Pharma Corp.

[{"type":"image","alt":"NervGen Pharma Corp.","displaySize":"","headline":null,"caption":"NervGen Pharma Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/on65M5UubYEttdyg2cfkEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22","width":300,"height":92}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate at multiple upcoming investor conferences.","length":547,"tagName":"p"},{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 25-26, 2026","length":81,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:25%;width:25%;min-width:25%;vertical-align:top;","val":[{"type":"text","content":"Format:","length":7,"tagName":"p","attribs":{}}]},{"style":"max-width:75%;width:75%;min-width:75%;vertical-align:top;","val":[{"type":"text","content":"Corporate Presentation and 1x1 Investor Meetings","length":48,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Presentation Date:","length":18,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Wednesday, February 25th","length":24,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"12:40 – 1:10 pm ET","length":18,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Location:","length":9,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Virtual","length":7,"tagN...

More updates from Nervgen Pharma Corp.

spinal cord injuryThe Companyneurologic conditionsNervGen Pharma Corp.biopharmaceutical companyAdam RogersCorporate Presentationinvestor conferencesCompany